[Federal Register Volume 84, Number 146 (Tuesday, July 30, 2019)]
[Notices]
[Pages 36945-36946]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-16166]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Catalent Pharma
Solutions, LLC
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before August 29, 2019.
Such persons may also file a written request for a hearing on the
application on or before August 29, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement
[[Page 36946]]
Administration, Attn: Administrator, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ,
8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug
Enforcement Administration, Attn: DEA Federal Register Representative/
DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on May 31, 2019, Catalent Pharma Solutions, LLC, 3031
Red Lion Road, Philadelphia, Pennsylvania 19114 applied to be
registered as an importer of the following basic class of controlled
substance:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid............. 2010 I
------------------------------------------------------------------------
The company plans to import finished dosage unit products
containing gamma-hydroxybutyric acid for clinical trials, research, and
analytical activities.
Dated: July 16, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-16166 Filed 7-29-19; 8:45 am]
BILLING CODE 4410-09-P